CN1976946A - 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用 - Google Patents

诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用 Download PDF

Info

Publication number
CN1976946A
CN1976946A CNA2005800215962A CN200580021596A CN1976946A CN 1976946 A CN1976946 A CN 1976946A CN A2005800215962 A CNA2005800215962 A CN A2005800215962A CN 200580021596 A CN200580021596 A CN 200580021596A CN 1976946 A CN1976946 A CN 1976946A
Authority
CN
China
Prior art keywords
epi
cell
hcv
dna
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800215962A
Other languages
English (en)
Chinese (zh)
Inventor
黄琉炅
金南京
朴庭旼
林玉宰
朴万勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of CN1976946A publication Critical patent/CN1976946A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800215962A 2004-07-03 2005-07-04 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用 Pending CN1976946A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040051782 2004-07-03
KR20040051782 2004-07-03

Publications (1)

Publication Number Publication Date
CN1976946A true CN1976946A (zh) 2007-06-06

Family

ID=35783125

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800215962A Pending CN1976946A (zh) 2004-07-03 2005-07-04 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用

Country Status (6)

Country Link
US (1) US20080112977A1 (https=)
EP (1) EP1778719A1 (https=)
JP (1) JP2008505636A (https=)
KR (1) KR100790646B1 (https=)
CN (1) CN1976946A (https=)
WO (1) WO2006004362A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174522A (zh) * 2011-02-24 2011-09-07 杭州师范大学 一种4-1bbl蛋白的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101854945B (zh) * 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
WO2000011186A1 (en) * 1998-08-21 2000-03-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified hcv peptide vaccines
EP1137792B9 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
PL211872B1 (pl) * 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
JP2003064096A (ja) 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc C型肝炎ウイルス特異的細胞障害性t細胞認識エピトープ

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174522A (zh) * 2011-02-24 2011-09-07 杭州师范大学 一种4-1bbl蛋白的制备方法
CN102174522B (zh) * 2011-02-24 2013-11-06 杭州师范大学 一种4-1bbl蛋白的制备方法

Also Published As

Publication number Publication date
WO2006004362A1 (en) 2006-01-12
US20080112977A1 (en) 2008-05-15
EP1778719A1 (en) 2007-05-02
KR100790646B1 (ko) 2008-01-02
JP2008505636A (ja) 2008-02-28
KR20060049824A (ko) 2006-05-19

Similar Documents

Publication Publication Date Title
CN1093881C (zh) 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
CN1650012A (zh) 来自致病病毒的备选阅读框所编码的抗原
CN1118572A (zh) Hla-a2.1组合肽及其用途
CN1833022A (zh) 包含HCV的多蛋白NS3/NS4和多肽NS5b的组合物,包括相应核酸序列的表达载体及它们的治疗应用
CN1671423A (zh) 新型嵌合cd154
CN101048502A (zh) 具有自主复制能力的经修饰的人丙型肝炎病毒基因组rna
CN1931365A (zh) Hcv e1e2疫苗组合物
CN1845995A (zh) 用于破坏宿主对外来抗原的耐受性的嵌合抗原
CN1460111A (zh) 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
CN1836042A (zh) 用于基因沉默的hbv和hcv保守序列
CN1822856A (zh) Hcv疫苗
CN1833024A (zh) 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
CN1198933C (zh) 登革病毒的前m/m蛋白的表位、合成肽
CN1942585A (zh) 含人丙型肝炎病毒全长基因组的核酸构建物、核酸构建物转入其中的重组全长病毒基因组复制型细胞和生产丙型肝炎病毒颗粒的方法
CN1738834A (zh) Hcv 疫苗
CN1281748C (zh) 为改善IL-12活性而突变的IL-12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1509337A (zh) IFNα-17基因的新的多核苷酸和多肽
CN1718243A (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
CN1255540C (zh) 一株疫苗诱导的乙型肝炎病毒株及其应用
CN1238011A (zh) 口蹄疫病毒的免疫原性肽
CN1874787A (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
CN1856503A (zh) 来源于c型肝炎病毒的肽
CN1280307C (zh) 细胞毒性t淋巴细胞
CN1976946A (zh) 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
CN1810970A (zh) 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication